Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Acquisition

7 Mar 2006 07:04

Marchpole Holdings PLC07 March 2006 FOR IMMEDIATE RELEASE 7 March 2006 Marchpole Holdings plc ("Marchpole") MARCHPOLE COMPLETES ACQUISITION OF MODA AMERICA LLC Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac / Rossignol,Emanuel Ungaro and Ungaro), today announces the successful completion of itsacquisition of the whole of the issued share capital of Moda America LLC. Moda America is the US licensee for Emanuel Ungaro and the acquisition bringsfive key benefits : - Based on turnover of $20m in the year to 31st December 2005, primarily from major blue chip U.S. retail customers such as Federated, Macy's, Robinson May and Marshall Fields, the Directors anticipate that sales and margins will increase as Moda benefits from Marchpole's design, sourcing and production base. - Marchpole will be launching the diffusion Ungaro homme collection in the UK from Spring/Summer 2007. This collection will be priced at similar levels to the current YSL ranges which the Directors expect to have significant mass market appeal across Marchpole's existing customer base. - The presence of Marchpole in North America and the new distribution relationships accessed through this acquisition will facilitate the launch of the Jean Charles de Castelbajac brands in the US from Autumn/Winter 2006. - Marchpole's relationship with Emanuel Ungaro has been strengthened further, illustrated by the granting of womenswear distribution rights for the US. - The Emanuel Ungaro mainline collection, already established by Marchpole in Europe and Asia, will now be launched into the US, Canada and South America. Total consideration for the acquisition will be $5.5m in cash, to be satisfiedfrom the Company's existing resources, of which $1.0m was paid on completion andthe balance of $4.5m payable on 31st July 2006. Current Trading Outlook With the third quarter now complete and deliveries underway for the new Spring/Summer 2006 collections, the Directors remain confident of the Company meetingmarket expectations of profit before taxation for the current financial year of£5.0m. In addition, the Directors are intending to implement proposals to enable theCompany to buy-in its issued share capital subject to shareholder approval asthey believe that the current share price undervalues the Company and does notadequately reflect the strong future prospects of the business. Chairman Chris Phillips commented: "The acquisition contributes significantly to our strategic objective ofbecoming a truly worldwide manager of luxury brands". For further information contact: MarchpoleGreg Tufnell - Chief Executive 020 7908 7700 BuchananTim Thompson / Nicola Cronk 020 7466 5000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.